ArticleIndian journal of surgical oncology2025
Clinical Progression on Neoadjuvant Chemotherapy: An Indicator of Poor Outcomes in Extremity Osteosarcoma.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TMEM158-mediated TGF-β signaling pathway modulates the sensitivity of TP53-deficient osteosarcoma to USP14 inhibitors.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a matrix-producing neoplasm. Most patients are treated with neoadjuvant chemotherapy (NACT. Various parameters are available for response assessment which include radiological and histological criteria. Data on clinical responses such as pain response and size assessment is meagre. In this study, we aimed to analyze if clinical assessment used for response evaluation can predict prognosis in patients receiving neoadjuvant chemotherapy for extremity osteosarcoma. All patients diagnosed with osteosarcoma and who underwent treatment with curative intent between January 2000 and December 2018 were identified. Patients who had progression were identified and whether clinical progression impacted overall survival (OS) and disease-free survival (DFS) was analyzed. Forty-three patients who had progression on NACT were identified. When compared to patients who did not have clinical progression, more patients in the clinical progression group had large tumors (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.